Search by Abstract Number Results

Abstract Number: 0835 • ACR Convergence 2024
Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid NanoparticleEncoding an Anti-CD19 CAR mRNA(CPTX2309)
Yan Zhang¹, Brittany Ross¹, Diana Galvan¹, Yanjie Bao¹, Daiki Matsuda¹, Shaun Grosskurth¹, Iago Pinal-Fernandez², Maria Casal-Dominguez³, Gregor Adams¹, Michael Rosenzweig¹, Ramin Farzaneh-Far¹, Priya Karmali¹, Adrian Bot¹, Andrew Mammen² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²NIH, Bethesda, MD, ³NIH, Bathesda, MD
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease (AID)…
Abstract Number: 0835 • ACR Convergence 2023
Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial
Andrew Cope¹, Marianna Jasenecova², Joana Vasconcelos³, Andrew Filer⁴, Karim Raza⁵, Sumera Qureshi², Maria Antonietta D'Agostino⁶, Iain McInnes⁷, John Isaacs⁸, Arthur Pratt⁹, Benjamin A Fisher⁴, Christopher Buckley¹⁰, Paul Emery¹¹, Pauline Ho¹², Maya Buch¹³, Coziana Ciurtin¹⁴, René Toes¹⁵, Thomas Huizinga¹⁵, Dirkjan van Schaardenburg¹⁶, Caroline Caroline¹⁷ and Toby Prevost³, ¹King's College London, London, United Kingdom, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's College London, London, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁹Translational & Clinical Research Institute, University of Newcastle, Newcastle, United Kingdom, ¹⁰University of Oxford, Oxford, United Kingdom, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹³University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ¹⁴Centre for Rheumatology Research, University College London, London, United Kingdom, ¹⁵Leiden University Medical Center, Leiden, Netherlands, ¹⁶Reade, Amsterdam, Netherlands, ¹⁷King's Clinical Trials Unit, King's College London, London, United Kingdom
Background/Purpose: The definition of higher risk states for rheumatoid arthritis (RA) has been refined in more recent years through inclusion of serum autoantibodies and symptom…
Abstract Number: 0835 • ACR Convergence 2022
Temporal Trends in Prosthetic Joint Infection
Anne Bass¹, Yi Zhang,², Peter Sculco², huong do², Kayla Glaser², alberto Carli², Mark Figgie² and Susan Goodman², ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: Prosthetic joint infection (PJI) is a dreaded complication of total knee replacement (TKR) that usually requires removal of the prosthesis, treatment with antibiotics and…
Abstract Number: 0835 • ACR Convergence 2021
Immunogenicity of Rituximab Biosimilar GP2013 in Chronic Inflammatory Rheumatic Disorders in Daily Clinical Practice
Jerome Avouac¹, Rodolphe Cougnaud-Murail¹, Claire Goulvestre², Sophie Dumas³, Anna Molto⁴, Corinne Miceli-Richard⁵, ornella conort³, Frederic Batteux² and Yannick Allanore¹, ¹Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ²Université de Paris, Service d'Immunologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ³Université de Paris, Service de pharmacie, Hôpital Cochin, AP-HP.CUP, Paris, France, ⁴Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ⁵Assistance Publique Hpitaux de PAris, Paris, France
Background/Purpose: To study in daily practice the risk of immunogenicity of patients treated with rituximab (RTX) biosimilar GP2013 for their chronic inflammatory rheumatic disorder.Methods: A…
Abstract Number: 0835 • ACR Convergence 2020
Pathogenic Effect of Chronic Stress-induced interleukin-12/23p40 on Neuropsychiatric System in Lupus-prone Mouse
Nobuya Abe¹, Kenji Oku¹, Yuichiro Fujieda¹, Nobuhiko Takahashi², Kohei Karino¹, Michihito Kono¹, Masaru Kato¹, Yuki Tanaka³, Rie Hasebe⁴, Olga Amengual¹, Miwako Yamasaki⁵, Masahiko Watanabe⁵, Masaaki Murakami³ and Tatsuya Atsumi⁶, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ²Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ³Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁴Biomedical Animal Research Laboratory, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁵Department of Anatomy, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose:Neuropsychiatric system is one of the major organs affected in systemic lupus erythematosus (SLE). However, the pathogenesis of neuropsychiatric SLE (NPSLE) has not been fully…

Search Again »

Didn't find what you were looking for? Try the Advanced Search »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].